Skip to main content

Advertisement

SpringerLink
Log in

Combination Therapy of Denosumab and Teriparatide in Osteoporosis

  • Review Article
  • Published:
Indian Journal of Orthopaedics Aims and scope Submit manuscript

Abstract

Osteoporosis is a chronic disease that often requires long-term treatment for many years. The clinician should know about all the drugs that are currently being used for treatment in osteoporosis and their mechanism of action, efficacy, safety profile, mode of administration and number of years they can be given safely without causing significant adverse effects. The categories of drugs that are currently being used for osteoporosis are antiresorptives such as oral and intravenous bisphosphonates, denosumab, and anabolics like teriparatide. This article will focus on the combination therapy of denosumab and teriparatide and will discuss how this combination is better than other class of drugs when given alone or in combination in osteoporosis patients especially those who are at high risk of fragility fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Tsai, J. N., Uihlein, A. V., Burnett-Bowie, S. M., Neer, R. M., Derrico, N. P., Lee, H., Bouxsein, M. L., & Leder, B. Z. (2016). Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). The Journal of Clinical Endocrinology & Metabolism, 101(5), 2023–2030.

    Article  CAS  Google Scholar 

  2. Tsai, J. N., Uihlein, A. V., Lee, H., et al. (2013). Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. The Lancet, 382, 50–56.

    Article  CAS  Google Scholar 

  3. Leder, B. Z., Tsai, J. N., Uihlein, A. V., et al. (2014). Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): A randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 99, 1694–1700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tsai, J. N., Lee, H., David, N. L., Eastell, R., & Leder, B. Z. (2019). Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. The Lancet Diabetes & Endocrinology, 7(10), 767–775. https://doi.org/10.1016/S2213-8587(19)30255-4. Epub 2019 Aug 22.

    Article  CAS  Google Scholar 

  5. Ramchand, S. K., David, N. L., Lee, H., Bruce, M., Bouxsein, M. L., Leder, B. Z., & Tsai, J. N. (2021). Effects of combination denosumab and high-dose teriparatide administration on bone microarchitecture and estimated strength: The DATA-HD HR-pQCT study. Journal of Bone and Mineral Research, 36, 41–51.

    Article  CAS  PubMed  Google Scholar 

  6. Black, D. M., Greenspan, S. L., Ensrud, K. E., et al. (2003). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal of Medicine, 349, 1207–1215.

    Article  CAS  PubMed  Google Scholar 

  7. Finkelstein, J. S., Wyland, J. J., Lee, H., & Neer, R. M. (2010). Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism, 95, 1838–1845.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cosman, F., Eriksen, E. F., Recknor, C., et al. (2011). Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 26, 503–511.

    Article  CAS  PubMed  Google Scholar 

  9. Finkelstein, J. S., Leder, B. Z., Burnett, S. M., et al. (2006). Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. Journal of Clinical Endocrinology and Metabolism, 91, 2882–2887.

    Article  CAS  PubMed  Google Scholar 

  10. Nakamura, Y., Suzuki, T., Kamimura, M., et al. (2017). Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Research, 5, 16055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang, W. Y., Chen, L. H., Ma, W. J., & You, R. X. (2023). Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: A network meta-analysis of randomized controlled trials. European Review for Medical and Pharmacological Sciences, 27(17), 8253–8268. https://doi.org/10.26355/eurrev_202309_33586

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gurugram, India

    Mohit Kumar Arora, Lalit Kumar & Sunil Marwah

Authors
  1. Mohit Kumar Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lalit Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunil Marwah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohit Kumar Arora.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard statement

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent

For this type of study informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arora, M.K., Kumar, L. & Marwah, S. Combination Therapy of Denosumab and Teriparatide in Osteoporosis. JOIO 57 (Suppl 1), 147–149 (2023). https://doi.org/10.1007/s43465-023-01051-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43465-023-01051-w

Keywords

Search

Navigation